Angelini

Angelini Pharma and Quiver Bioscience Collaborate to Advance Genetic Epilepsy Therapies

Partnership Aims to Uncover Novel Therapies for Developmental and Epileptic Encephalopathies Why is the discovery of new therapies for genetic epilepsies so critical? Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience, a discovery technology and therapeutics…

Read MoreAngelini Pharma and Quiver Bioscience Collaborate to Advance Genetic Epilepsy Therapies
Synthekine

Synthekine Inc. Appoints John A. Orwin as Board Chair to Lead Clinical Expansion

Biotech Leader Takes Helm as Synthekine Advances Phase 2 Cancer Study In the rapidly evolving landscape of biotechnology, where precision and innovation are paramount, Synthekine Inc. is making a strategic move to solidify its position. The company, which specializes in engineered cytokine…

Read MoreSynthekine Inc. Appoints John A. Orwin as Board Chair to Lead Clinical Expansion
Pelage Pharmaceuticals

Pelage Pharmaceuticals Strengthens Leadership and Board with Strategic Appointments

Pelage Pharmaceuticals Appoints New Board Member and Promotes Key Executives In the competitive landscape of regenerative medicine, where innovative solutions for hair loss are increasingly in demand, Pelage Pharmaceuticals is making strategic moves to solidify its position. The company, a clinical-stage biotechnology…

Read MorePelage Pharmaceuticals Strengthens Leadership and Board with Strategic Appointments
Bristol Myers Squibb

Bristol Myers Squibb Advances Alpha-Thalassemia Treatment With Reblozyl

Positive Top-Line Results for Reblozyl in Alpha-Thalassemia Study Is the treatment landscape for alpha-thalassemia about to change? Bristol Myers Squibb has announced positive top-line results from an ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl® (luspatercept-aamt) versus placebo for anemia in adults…

Read MoreBristol Myers Squibb Advances Alpha-Thalassemia Treatment With Reblozyl
Gilead

Gilead Sciences Acquires Arcellx for $7.8 Billion to Advance Cancer Immunotherapies

Gilead Sciences Seals $7.8 Billion Deal for Arcellx to Boost CAR T-Cell Therapy In the rapidly evolving landscape of cancer immunotherapies, where breakthroughs are crucial for patient outcomes, Gilead Sciences, Inc. has made a significant move. The biopharmaceutical giant has announced a…

Read MoreGilead Sciences Acquires Arcellx for $7.8 Billion to Advance Cancer Immunotherapies
AOP Health

AOP Health Advances Rare Disease Care With Collaborative Data and Patient Engagement

AOP Health Emphasizes Collaboration and Patient-Centered Information on Rare Disease Day 2026 Why is the diagnosis and treatment of rare diseases so challenging? AOP Health, a global enterprise group with roots in Austria, is dedicated to addressing this critical issue.…

Read MoreAOP Health Advances Rare Disease Care With Collaborative Data and Patient Engagement
Virion Therapeutics

Virion Therapeutics Advances HBV Functional Cure With Novel Immunotherapy

Virion Therapeutics Unveils Promising HBV Treatment at CROI Conference Is the global fight against chronic hepatitis B (CHB) finally turning a corner? Virion Therapeutics, LLC, a clinical-stage biotechnology company, is making significant strides with its novel T cell-based immunotherapy, VRON-0200.…

Read MoreVirion Therapeutics Advances HBV Functional Cure With Novel Immunotherapy